Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis
Recruiting · Phase 1, Phase 2 · NCT06668493
Conditions: Low-grade Upper Tract Urothelial Carcinoma
At a glance
- Research payments reported, 2025
- $105,611
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 20
About the trial
- Sponsor
- Ferring Pharmaceuticals
- Tested
- Nadofaragene Firadenovec (drug)
- Dates
- Started 2025-06-12; completion 2029-11-30
- Results posted
- Not yet
The primary purpose of this trial is to evaluate the safety \& tolerability of Nadofaragene Firadenovec in subjects with LG-UTUC. To help with this evaluation, a safety lead-in period will be conducted for the first 6 subjects. Complete response is at 3 or 6 months defined as absence of any UTUC in the renal pelvis.
From ClinicalTrials.gov, last updated 2026-09-15. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Ferring Pharmaceuticals As reported $105,611 in research payments for this study in 2025 (3 payments).
Products named: Adstiladrin
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Andrew F. Trainer, M.D. Urology · Omaha, NE
- Jonathan A. Coleman, M.D. Urology · New York, NY
- Phillip M. Pierorazio, MD Urology · Philadelphia, PA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Memorial Sloan Kettering Cancer Center $49,157
- Hospital of Univ of Pennsylvania, PA $37,174
- The Urology Center PC $19,280
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.